Over the last few years, scientists and entrepreneurs have flocked to developing medicines that target RNA, the genetic ...

Dawnzera is the first and so far only RNA-targeting therapy approved as a prophylactic treatment for hereditary angioedema ...

The ability to correct disease-causing genetic mistakes using genome editors holds great promise in medicine, but it is not ...

In June, the monoclonal antibody garadacimab (Andembry) was approved for prevention of HAE attacks at a dose of once monthly ...

In 1957, just four years after Francis Crick and other scientists solved the riddle of DNA’s structure—the now famous double ...

This review, led by Prof. Bochen Jiang at the School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, provides a comprehensive ...

The approval makes donidalorsen the only treatment in the US for hereditary angioedema that is an RNA-targeted prophylactic.

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that the U.S. Food and Drug Administration (FDA) has approved ...

As aging progresses, the quality of DNA and proteins inside cells declines, which is known to be the cause of various ...

On Thursday, the U.S. Food and Drug Administration (FDA) approved Ionis Pharmaceuticals, Inc.’s (NASDAQ:IONS) Dawnzera ...

Skyhawk Therapeutics, Inc., a leader in the discovery and development of small molecules that modulate RNA expression, today ...

Waltham, Massachusetts–based Skyhawk Therapeutics has been collecting collaborations with larger companies in spades since ...